Portfolio company Curevo Vaccine agreed to be acquired by Eli Lilly for up to $1.5B to advance its next-generation shingles vaccine.
Curevo Vaccine is a clinical-stage biotech company dedicated to developing next-generation non-mRNA vaccines, focusing on improving tolerability, efficacy, and accessibility of vaccines for infectious diseases, specifically shingles and chickenpox
Curevo Vaccine is a clinical-stage biotech company dedicated to developing next-generation non-mRNA vaccines, focusing on improving tolerability, efficacy, and accessibility of vaccines for infectious diseases, specifically shingles and chickenpox.